Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...
Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...
Woman & Home on MSN
Dr Amir Khan reveals how to shorten a cold by '2 and a quarter days' with one simple change
Vitamin C has been found to shorten a cold as well, but it won't make a difference if you're already showing symptoms, per ...
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, nasal congestion and nasal polyps in patients aged 6 years ...
Nasal irrigation has been used to treat the common cold for thousands of years, and modern science shows that it works.
Tezspire is the first biologic approved for CRSwNP targeting TSLP, expanding its respiratory indications. The drug acts on airway epithelium, inhibiting TSLP, an early-stage inflammatory cytokine. The ...
Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...
THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE ® (tezepelumab-ekko) for the ...
Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...
Investing.com -- AstraZeneca and Amgen have received European Union approval for Tezspire as an add-on therapy for adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) who haven’t ...
Please provide your email address to receive an email when new articles are posted on . The FDA on Friday approved a new biologic as add-on maintenance treatment for inadequately controlled chronic ...
WEDNESDAY, Oct. 29, 2025 (HealthDay News) -- Females have a higher odds of chronic rhinosinusitis (CRS) without nasal polyps than men, according to a study published online Oct. 23 in JAMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback